Topic: DNA

JD Supra Corporate Brief: Fair Working Conditions, WARN Act Notices, Deferred Employee Compensation, Human Gene Patents

It’s Friday, and here at the JD Supra Corporate Brief, that means an extra Danish on the way into the office. Care to join us? How can multinationals ensure fair working conditions for workers on the other side of the globe? (NAVEX Global) The exemption from WARN Act notices for companies in Chapter 11 just… Read more »

DNA Eligible for Patent Protection, Court Rules in Myriad (Again)

“Isolated DNA molecules are patent-eligible, reaffirmed the U.S. Court of Appeals for the Federal Circuit in Ass’n for Molecular Pathology et al. v. Myriad Genetics, Inc. et al., lifting a cloud of uncertainty over DNA composition patents. ‘The isolated DNA molecules before us are not found in nature. They are obtained in laboratory and are… Read more »

Supreme Court Remands Myriad Following Rejection of Prometheus Patents

When a unanimous Supreme Court earlier this month rejected Prometheus’ claims that isolated DNA sequences are patentable (see Mayo v. Prometheus: SCOTUS Issues Landmark IP Law Opinion), many wondered if the diagnostic testing patents held by Myriad Genetics would meet a similar fate. It took less than one week to get the answer. On March… Read more »